These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22088996)

  • 1. How should we use bevacizumab in patients with non-small cell lung cancer?
    Kim YH; Mishima M
    J Thorac Oncol; 2011 Dec; 6(12):2145-6. PubMed ID: 22088996
    [No Abstract]   [Full Text] [Related]  

  • 2. Complete regression of a non-small cell lung cancer choroidal metastasis with intravitreal bevacizumab.
    D'Antonio C; Viterbo A; Romiti A; Enrici MM; Lauro S; Marchetti P
    J Thorac Oncol; 2012 Feb; 7(2):468-9. PubMed ID: 22252564
    [No Abstract]   [Full Text] [Related]  

  • 3. Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC.
    Cancer Discov; 2014 Nov; 4(11):OF18. PubMed ID: 25367959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab in non-small-cell lung cancer: a review.
    Planchard D
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1163-79. PubMed ID: 21916570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab in non-small cell lung cancer: an overview of practice in the era of molecular testing.
    Snee M
    Clin Oncol (R Coll Radiol); 2014 Aug; 26(8):468-72. PubMed ID: 24909702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab as adjuvant therapy for lung cancer does not help patients over 65.
    Roehr B
    BMJ; 2012 Apr; 344():e2855. PubMed ID: 22517975
    [No Abstract]   [Full Text] [Related]  

  • 7. Bevacizumab in lung cancer: lackluster performance and unjustified expense?
    Dasanu CA
    J Oncol Pharm Pract; 2012 Sep; 18(3):381-2. PubMed ID: 22777997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of bevacizumab in non-small cell lung cancer: an update.
    Lauro S; Onesti CE; Righini R; Marchetti P
    Anticancer Res; 2014 Apr; 34(4):1537-45. PubMed ID: 24692680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intramedullary spinal cord hemorrhage after treatment with bevacizumab in a long-term survivor with metastatic non-small-cell lung cancer.
    Arreola KN; Ying J; Hughes R; Gerber DE; Kim DW
    J Thorac Oncol; 2014 Aug; 9(8):e60-1. PubMed ID: 25157780
    [No Abstract]   [Full Text] [Related]  

  • 10. The proportion of patients with metastatic non-small cell lung cancer potentially eligible for treatment with bevacizumab: a single institutional survey.
    Velcheti V; Viswanathan A; Govindan R
    J Thorac Oncol; 2006 Jun; 1(5):501. PubMed ID: 17409907
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinicopathological factors affecting progression-free survival of patients with previously treated advanced non-small cell lung cancer after S-1 therapy with or without bevacizumab.
    Masago K; Fujita S; Hata A; Kaji R; Ohtsuka K; Okuda C; Takeshita J; Katakami N
    Anticancer Res; 2014 Dec; 34(12):7467-72. PubMed ID: 25503189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the future of non-small cell lung cancer treatment.
    Ramalingam S
    Manag Care; 2005 Feb; 14(2 Suppl):9-13; discussion 13-4. PubMed ID: 15776956
    [No Abstract]   [Full Text] [Related]  

  • 13. Bevacizumab in lung cancer: hurdles in clinical development.
    Pirker R
    Lancet Oncol; 2010 Aug; 11(8):703-4. PubMed ID: 20650687
    [No Abstract]   [Full Text] [Related]  

  • 14. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab.
    Gray J; Murren J; Sharma A; Kelley S; Detterbeck F; Bepler G
    J Thorac Oncol; 2007 Jun; 2(6):571-3. PubMed ID: 17545855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bevacizumab in the treatment of non-small cell lung cancer].
    Knuuttila A; Rouhos A; Karjalainen EM; Riska H; Pietiläinen M; Paunu N; Salomaa ER
    Duodecim; 2009; 125(4):361-8. PubMed ID: 19358416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer.
    Riess JW; Logan AC; Krupitskaya Y; Padda S; Clément-Duchêne C; Ganjoo K; Colevas AD; Pedro-Salcedo MS; Kuo CJ; Wakelee HA
    Cancer Invest; 2012 Mar; 30(3):231-5. PubMed ID: 22360362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis inhibition in the treatment of lung cancer.
    Vokes E; Herbst R; Sandler A
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging antiangiogenic therapies for non-small-cell lung cancer.
    Blakely C; Jahan T
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1607-18. PubMed ID: 21999134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Problems involved in the clinical trials for non-small cell lung carcinoma.
    Saijo N
    Cancer Treat Rev; 2012 May; 38(3):194-202. PubMed ID: 21775064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.